Enliven Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Enliven Therapeutics, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, to address key corporate proposals including director elections and a significant increase in authorized shares.
NASDAQ
Enliven Therapeutics will hold its annual stockholders meeting virtually on June 24, 2025, to elect directors and ratify the appointment of its accounting firm.
NASDAQ
Enliven Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 24, 2025, featuring director elections and ratification of the company's independent auditor.
NASDAQ
Enliven Therapeutics will hold its annual stockholders meeting on June 18, 2024, to vote on the election of directors, ratification of the auditor, and amendments to the certificate of incorporation and equity incentive plan.
NASDAQ
Enliven Therapeutics will conduct its 2024 Annual Meeting of Stockholders virtually on June 18, 2024, to vote on director elections, auditor ratification, officer liability limitation, and an equity incentive plan amendment.